Prudential Upgrades CuraGen Rating to Buy

Analyst Charles Duncan likes the company's strong cash position and its committed product development funding

CuraGen Corp. (CRGN ) shares were sharply higher after the genomics research firm announced that it had entered into two alliances with pharmaceuticals giant Bayer. Prudential Securities upgraded its investment recommendation on the shares to strong buy from accumulate.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.